Showing posts with label Ductal carcinoma in situ. Show all posts
Showing posts with label Ductal carcinoma in situ. Show all posts

Wednesday, 16 March 2022

Breast Surgery Bulletin - March 2022

 

Local treatment options for young women with ductal carcinoma in situ: A systematic review and meta-analysis comparing breast conserving surgery with or without adjuvant radiotherapy, and mastectomy

 

by Ju-Chun Chien, Wen-Shan Liu, Wei-Tzu Huang, Liang-Chung Shih, Wen-Chung Liu, Yu-Chia Chen, Kang-Ju Chou, Yow-Ling Shiue, Pei-Chin Lin 

 

The Breast: VOLUME 63, P29-36, JUNE 01, 2022

 

 

Purpose

Young age is associated with poor prognosis in ductal carcinoma in situ (DCIS) of female breast and controversy exists regarding the optimal treatment modality for young patients. We aimed to compare treatment outcomes among breast conserving surgery (BCS), BCS with adjuvant radiotherapy (BCS + RT), and total mastectomy (MT) for young DCIS women.

Methods

PubMed, Cochrane, and Embase were searched for studies reporting comparative results among BCS, BCS + RT, or MT in ≤50 years old (y/o) DCIS females. Study quality was assessed and meta-analysis with subgroup analysis was performed to pool the effect sizes of the outcomes-of-interest.

Results

We included 3 randomized control trials and 18 observational studies. For DCIS women ≤50 y/o, RT following BCS significantly reduced the risk for ipsilateral breast tumor recurrence (IBTR) (HR = 0.66, 95% CI 0.50–0.87). However, the benefit was less robust in extremely young patients and with long follow-ups. RT revealed no statistically significant preventive effect on ipsilateral invasive recurrence (HR = 1.38, 95% CI 0.98–1.94). On the other hand, MT yielded the lowest IBTR (BCS + RT vs MT: HR = 4.4, 95% CI 2.06–9.40), both in ipsilateral DCIS recurrence and ipsilateral invasive recurrence. There was great heterogeneity and could not reach an evident conclusion concerning survival outcomes.

Conclusion

This study highlighted the varying effect of RT for young DCIS females. The local control benefit of MT was definite without survival differences observed. Our study provided a moderate certainty of evidence to guide the treatment for young DCIS women. Further age-specific prospective trial is warranted.

 

Monday, 18 September 2017

Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: Critical review

Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: Critical review
Toss M et al
The Breast October 2017 Volume 35, Pages 151–156

The high proportion of ductal carcinoma in situ (DCIS) presented in mammographic screening and the relatively low risk of progression to invasive disease have raised questions related to overtreatment. Following a review of current DCIS management protocols a more conservative approach has been suggested. Clinical trials have been introduced to evaluate the option of avoiding surgical intervention in a proportion of patients with DCIS defined as “low-risk” using certain clinicopathological criteria.

Tuesday, 4 July 2017

Evaluation of margins in invasive carcinoma and ductal carcinoma in situ: The pathologist's perspective

Evaluation of margins in invasive carcinoma and ductal carcinoma in situ: The pathologist's perspective

Schnitt SJ
The Breast 
Article in Press

A variety of patient factors, treatment factors and pathologic factors are associated with an increased risk of ipsilateral breast tumor recurrence (local recurrence) after breast conservation therapy for invasive breast cancer and ductal carcinoma in situ (DCIS). Arguably, the most important of these is the status of the microscopic margins of excision of the resected breast specimen. Until recently there has been no agreement on what constitutes an adequate negative lumpectomy margin for patients with either invasive breast cancer or DCIS managed with the breast conserving approach  and this issue has never been addressed in randomized clinical trials.

Postoperative radiotherapy after DCIS: Useful for whom?

Postoperative radiotherapy after DCIS: Useful for whom?

Karlsson P
The Breast 
Article in Press

The number of patients with ductal carcinoma in situ (DCIS) increases with more widely used screening mammography programs. DCIS accounts for approximately 20% of all new breast cancer diagnoses in these programs and the natural course of this heterogeneous group of pre-invasive lesions is not fully known. Better definition of subgroups benefitting from radiotherapy and knowledge on the natural course of DCIS are important issues for the future management of DCIS.Four large randomized trials have studied the effects of postoperative radiotherapy after breast conserving surgery in patients with wider spectrum of DCIS and all of them have shown radiotherapy to halve the risk of ipsilateral events, however, without any significant effect on breast cancer mortality.

Tuesday, 18 October 2016

Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS)

Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS)

Groen EJ et al

The Breast: Article in Press

With the widespread adoption of population-based breast cancer screening, ductal carcinoma in situ (DCIS) has come to represent 20–25% of all breast neoplastic lesions diagnosed. Current treatment aims at preventing invasive breast cancer, but the majority of DCIS lesions will never progress to invasive disease. Still, DCIS is treated by surgical excision, followed by radiotherapy as part of breast conserving treatment, and/or endocrine therapy. This implies over-treatment of the majority of DCIS, as less than 1% of DCIS patients will go on to develop invasive breast cancer annually.

Wednesday, 26 March 2014

Mastectomy rates for ductal carcinoma in situ vary widely in UK

Mastectomy rates for ductal carcinoma in situa vary widely in UK, audit shows [news item]. BMJ 2014; 348:g2332

Mayor, S.

http://www.bmj.com/content/348/bmj.g2332?rss=1&hwoasp=authn%3A1395931440%3A4044144%3A3266341127%3A0%3A0%3AKU2BGBsYX8ly%2BjhKOx1Tkg%3D%3D

Data from the UK NHS Breast Cancer Screening Programme show significant variation between hospitals in the number of women with ductal carcinoma in situ undergoing mastectomy when lumpectomy would normally be indicated, shows an audit reported last week at the European Breast Cancer Conference.

Wednesday, 20 November 2013

A review of the management of ductal carcinoma in situ following breast conserving surgery

A review of the management of ductal carcinoma in situ following breast conserving surgery.The breast, Dec 2013, Vol. 22(6), p.1019-25.

Boxer, M.M., et al.

http://www.thebreastonline.com/article/S0960-9776(13)00246-4/abstract?rss=yes

Ductal carcinoma in situ (DCIS) is a heterogeneous, pre-malignant disease accounting for 10–20% of all new breast tumours. Evidence shows a statistically significant local control benefit for adjuvant radiotherapy (RT) following breast conserving surgery (BCS) for all patients. The baseline recurrence risk of individual patients varies according to clinical-pathological criteria and in selected patients, omission of RT may be considered, following a discussion with the patient. 


Thursday, 29 August 2013

Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery

Predictors of recurrence for ductal carinoma in situ after breast-conserving surgery. The lancet oncology, Aug 2013, Vol.14(9), p. e348-e357.

Benson, J.R. and Wishart, G.C.

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70135-9/abstract?rss=yes

Ductal carcinoma in situ (DCIS) constitutes a major public health problem, with up to half of screen-detected cancers representing pure forms of DCIS without evidence of invasion. A proportion of cases detected with routine screening would not have progressed to a life-threatening form of breast cancer during the patient's lifetime, and overdiagnosis of breast cancer is a cause for concern.

Tuesday, 8 February 2011

Breast Journal Vol 17 Iss 1 Jan - Feb 2011

Sentinel lymph node biopsy in breast cancer: an analysis of the maximum number of nodes requiring excision.
Gill J et al.
p3-8
Abstract only

Improvement in dcis detection rates by mri over time in a high-risk breast screening study.
Warner E et al.
p9-17
Abstract only

Breast reconstruction in women under 30: a 10-year experience.
Ellsworth WA et al.
p18-23
Abstract only

Outcome of small invasive breast cancer with no axillary lymph node involvement.
Sánchez-Muñoz A et al.
p32-8
Abstract only

The prognosis of tumors with only microscopic skin involvement without clinical t4b signs is significantly better than t4b tumors in breast carcinoma.
Duraker N et al.
p47-55
Abstract only

Sentinel lymph node biopsy after neo-adjuvant chemotherapy in breast cancer.
Stell VH et al
p71-4
Abstract only

Age <40> is an independent prognostic factor predicting inferior overall survival in patients treated with breast conservative therapy
Kim K et al.
p75-8
Abstract only


N.B. Articles for which there is no abstract are not included here.

Monday, 15 November 2010

Breast Journal Vol 16 Sept - Oct Supplement

A New Era in the Diagnosis and Treatment of Breast Cancer
Tabár L and Dean PB
S2-4
Abstract only


Challenges in the Interpretation of Breast Core Biopsies
Corben AD et al.
S5-9
Abstract only


Lobular Carcinoma, Not Only a Classic
Brogi E et al.
S10-4
Abstract only


Trends in the Surgical Treatment of Breast Cancer.
Morrow M
S17-9
Abstract only


Oncoplastic Surgery: The Evolution of Breast Cancer Treatment
De Lorenzi F
S20-1
Abstract only


Breast Cancer in Pregnancy.
Rovera F et al.
S22-5
Abstract only


The role of Micrometastatic Disease in Sentinel Lymph Node in Breast Cancer
Rovera F et al.
S26-8
Abstract only


Predictors of Loco-Regional Recurrence and Cancer-Related Death after Breast Cancer Surgery
Rausei S et al.
S29-33
Abstract only


Radiotherapy for Breast Cancer in the 21st Century
Powell S
S34-8
Abstract only


Capecitabine in Breast Cancer: The Issue of Cardiotoxicity During Fluoropyrimidine Treatment
Molteni LP et al
S45-8
Abstract only


The Surgical Management of Ductal Carcinoma In Situ
Kumar S and Sacchini V
S49-52
Abstract only

Monday, 19 April 2010

The Breast Journal Vol 16 Iss 2 Mar-Apr 2010

True recurrences and new primary tumors have different clinical features in invasive breast cancer patients with ipsilateral breast tumor relapse after breast-conserving treatment.
Yoshida, T et al.
p 127-133
Abstract only

Predicting non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement: evaluation of two scoring systems.
Sanjuan, A et al.
p 134-140
Abstract only

The use of oncoplastic reduction techniques to reconstruct partial mastectomy defects in women with ductal carcinoma in situ.
Song, HM et al.
p 141-146
Abstract only

Annals of Surgery Vol 251 Iss 4 April 2010

Avoiding Radiation After Breast-Conserving Surgery for Ductal Carcinoma In Situ of the Breast: Beyond the Margin
Rourke, Loren L. MD; Hunt, Kelly K. MD, FACS *
pg. 592-594

Sentinel Lymph Node Biopsy in Breast Cancer: Ten-Year Results of a Randomized Controlled Study
Veronesi, Umberto MD et al.
pg. 595-600

Long-Term Follow-Up Confirms the Oncologic Safety of Sentinel Node Biopsy Without Axillary Dissection in Node-Negative Breast Cancer Patients
Giuliano, Armando E. MD; Chung, Alice P. MD
pg. 601-603

Comparison of Skin-Sparing Mastectomy Versus Non–Skin-Sparing Mastectomy for Breast Cancer: A Meta-Analysis of Observational Studies
Lanitis, Sophocles MD et al.
pg. 632-639

MRI-Model to Guide the Surgical Treatment in Breast Cancer Patients After Neoadjuvant Chemotherapy
Straver, Marieke E. MD et al.
pg. 701-707

Monday, 20 April 2009

BMJ 2009 no. 338

Will ductal carcinoma in situ defeat breast cancer screening?
John R Benson
BMJ 2009;338 b957
Reality of ductal carcinoma in situ
Jane Flanders
BMJ 2009;338 b958
Tissue screening after breast reduction
Mohammed Keshtgar, Alireza Hamidian Jahromi, Tim Davidson, Paula Escobar, Patrick Mallucci, Afshin Mosahebi, and Michael Baum
BMJ 2009;338 b630

Tuesday, 2 September 2008

British Journal of Surgery Volume 95 Issue 10 2008

Pages: 1305
Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast (Br J Surg 2008; 95: 547-554)
P. Meijnen, E. J. Th. Rutgers
http://www3.interscience.wiley.com/cgi-bin/abstract/121393182/ABSTRACT
Published Online: 2 Sep 2008

Pages: 1305
Authors' reply: Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast (Br J Surg 2008; 95: 547-554)
B. Ansari, S. A. Ogston, A. M. Thompson
http://www3.interscience.wiley.com/cgi-bin/abstract/121393184/ABSTRACT
Published Online: 2 Sep 2008

Friday, 25 July 2008

Role of primary tumor characteristics in predicting positive sentinel lymph nodes

Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer.
American journal of surgery Jul 2008 (epub: 23 Apr 2008), vol. 196, no. 1, p. 81-7
Yi-Min, Krishnamurthy-Savitri, Kuerer-Henry-M et al
Abstract
BACKGROUND: We determined the incidence of positive sentinel lymph nodes (SLNs) in patients with ductal carcinoma in situ (DCIS) or microinvasive breast cancer (MIC) and the predictive factors of SLN metastasis in these patients. METHODS: Of 4,503 patients who underwent SLN dissection between March 1994 and March 2006 at our institution, we identified those with a preoperative diagnosis or final diagnosis of DCIS or MIC. Clinicopathologic factors were examined by logistic regression analysis. RESULTS: Of the 624 patients with a preoperative diagnosis of DCIS or MIC, 40 had positive SLNs (6.4%). Of the 475 patients with a final diagnosis of DCIS or MIC, 9 had positive SLNs (1.9%). Clinical DCIS size >5 cm was the only independent predictor of positive SLN for patients with a preoperative diagnosis and patients with a final diagnosis of DCIS or MIC. Core biopsy as the method of preoperative diagnosis and DCIS size >5 cm were independent predictors for a final diagnosis of invasive carcinoma in the 149 patients who had a preoperative diagnosis of DCIS or MIC. CONCLUSIONS: SLN dissection for patients with a diagnosis of DCIS should be limited to patients who are planned for mastectomy or who have DCIS size >5 cm. Patients who have a core-needle biopsy diagnosis of DCIS have a higher risk of invasive breast cancer on final pathologic assessment of the primary tumor. This information can be used in preoperative counseling of patients with DCIS regarding the timing of SLN biopsy.